Log in

OTCMKTS:MEOBFMesoblast Stock Price, Forecast & News

$2.70
0.00 (0.00 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.70
Now: $2.70
$2.70
50-Day Range
$2.05
MA: $2.26
$2.70
52-Week Range
$0.90
Now: $2.70
$3.90
VolumeN/A
Average Volume34,217 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MEOBF
CUSIPN/A
CIKN/A
Phone61 3 9639 6036

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees81
Next Earnings DateN/A
OptionableNot Optionable
$2.70
0.00 (0.00 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MEOBF News and Ratings via Email

Sign-up to receive the latest news and ratings for MEOBF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mesoblast (OTCMKTS:MEOBF) Frequently Asked Questions

How has Mesoblast's stock been impacted by COVID-19 (Coronavirus)?

Mesoblast's stock was trading at $1.45 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MEOBF stock has increased by 86.2% and is now trading at $2.70.
View which stocks have been most impacted by Coronavirus
.

Has Mesoblast been receiving favorable news coverage?

News stories about MEOBF stock have been trending somewhat positive recently, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mesoblast earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Mesoblast
.

Who are some of Mesoblast's key competitors?

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
  • Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
  • Dr. Kenneth M. Borow M.D., Exec. (Age 71)

What is Mesoblast's stock symbol?

Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."

How do I buy shares of Mesoblast?

Shares of MEOBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mesoblast's stock price today?

One share of MEOBF stock can currently be purchased for approximately $2.70.

What is Mesoblast's official website?

The official website for Mesoblast is www.mesoblast.com.

How can I contact Mesoblast?

The company can be reached via phone at 61 3 9639 6036.

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.